HTT

HTT

HTT Molekülinformation

Molecule Name
Huntingtin
Molekülalias
HTT,Htt,Huntingtin
Drug Development Progress
Anzahl der klinischen Arzneimittel10
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
Huntingtin,HD protein,HD,HTT,Huntington Disease Protein,IT15,Huntingtin (Huntington Disease),LOMARS,Huntingtin Protein
Molekülhintergrund
Huntingtin is the protein coded for by the HTT gene. Autosomal dominant mutation in the Huntingtin (Htt) protein is the cause of Huntington’s Disease (HD). In HD, the polyglutamine (polyQ) domain in the N-terminal sequenceof the protein is expanded beyond a threshold of 36 glutamines. mutant polyQ expansion strongly correlates in an inverse manner to disease age of onset.

HTT Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
TominersenRG-6042; RO-7234292; ISIS-443139Phase 3 ClinicalIonis Pharmaceuticals Inc
Huntington Disease
Details
SKY-0515SKY-0515Phase 3 ClinicalSkyhawk Therapeutics Inc
Huntington Disease; Nervous System Diseases
Details
VotoplamPTC-518; PTC518Phase 3 ClinicalPtc Therapeutics Inc
Huntington Disease
Details
WVE-003WVE-003Phase 2 ClinicalWave Life Sciences Ltd
Huntington Disease
Details
NA-841NA-841; NA841Phase 2 ClinicalBiomed Industries Inc
Huntington Disease
Details
SPK-10001SPK-10001; RG-6662; HTT miRNA GTPhase 2 ClinicalSpark Therapeutics Inc
Huntington Disease
Details
ER-2001ER-2001; ER2001Phase 2 ClinicalShenzhen Aima Biotechnology Co Ltd
Huntington Disease
Details
ARO-HTTARO-HTT; SRP-1005Phase 1 ClinicalArrowhead Pharmaceuticals Inc
Huntington Disease
Details
ALN-HTT-02ALN-HTT-02; ALN-HTT02Phase 1 ClinicalAlnylam Pharmaceuticals Inc
Huntington Disease
Details
PTC-607PTC-607Phase 1 ClinicalPtc Therapeutics Inc
Huntington Disease
Details